957147-18-1

Usage

Uses

Used in Oncology:
3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide is used as an FGFR inhibitor for targeting the fibroblast growth factor receptor pathway, which plays a crucial role in the development and progression of various cancers. Its application is particularly relevant in the treatment of lung and breast cancer, where FGFR inhibitors have shown promise.
Used in Pharmaceutical Research and Development:
In the pharmaceutical industry, 3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide is used as a research compound for understanding the pharmacological properties and potential therapeutic uses of FGFR inhibitors. Further research is needed to fully explore its efficacy, safety, and optimal application in cancer treatment.

Upstream product

• 1001203-03-7 3-ethynyl-4-methylbenzoic acid 
• 1416241-81-0 3-ethynyl-4-methylbenzoyl chloride 
• 943320-50-1 3-iodo-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)benzamide 
• 52107-98-9 3-iodo-4-methylbenzoyl chloride 
• 694499-26-8 4-(4-methylpiperazin-1-ylmethyl)-3-trifluoromethylaniline 
• 82998-57-0 3-iodo-4-toluic acid 
• 320-37-6 4-nitro-2-(trifluoromethyl)benzoic acid 
• 859027-06-8 (4-nitro-2-(trifluoromethyl)phenyl)methanol 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 
• 109-01-3 1-methyl-piperazine 
• 50551-17-2 4-nitro-2-(trifluoromethyl)benzaldehyde 
• 1066-54-2 trimethylsilylacetylene 
• 1255099-13-8 methyl 3-ethynyl-4-methylbenzoate 

Downstream Products

• 1421685-09-7 C₃₀H₂₉F₃N₆O₂ 
• 1421685-06-4 C₃₀H₂₉F₃N₆O 
• 1448705-58-5 C₃₆H₄₃F₃N₆O₂Si 
• 1421684-97-0 C₃₀H₂₈F₃N₅O 
• 1421684-98-1 C₃₀H₂₉F₃N₆O 
• 1421684-99-2 3-([1,2,4]triazolo[1,5-a]pyrimidin-6-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)-phenyl)benzamide 
• 1421685-07-5 C₃₂H₃₁F₃N₆O 
• 1431221-13-4 C₃₈H₄₅F₃N₆O₂Si 
• 1421685-08-6 C₃₅H₃₁F₃N₆O 
• 943319-70-8 ponatinib 

Relevant academic research and scientific papers

Urea-substituted alkynyl pyrimidine or urea-substituted alkynyl pyridine compound as well as composition and application thereof

The invention relates to urea-substituted alkynyl pyrimidine or urea-substituted alkynyl pyridine compounds with a formula (I) or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, pharmaceutical compositions containing the compounds, and applications of the compounds or compositions in drug preparation. The medicine can be used as kinase inhibitors such as ABL, ABL-T315I, KIT, VEGFR-2 and the like for treating related diseases.

KINASE INHIBITORS AND USES THEREOF

This invention described herein relates to compounds of general formula (I) : (I), in which variable groups are as defined herein, and to their preparation and use. Uses for the compounds and for compositions containing them include treatment of cancer and other diseases mediated by protein kinases, such as Bcr-Abl kinase, and mutants thereof, such as the T315I mutant.

Alkynyl pyrimidine or alkynyl pyridine compound as well as composition and application thereof

The invention relates to alkynyl pyrimidine or alkynyl pyridine compounds represented by a formula (I) or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof. The invention also discloses a pharmaceutical composition contain

3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF

The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT

In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in

A drug treating chronic granulocytic leukemia method for the preparation of

The invention relates to a preparation method of a drug for treating chronic granulocytic leukemia, belonging to the field of medical chemistry, and specifically relates to a preparation method of 3-[2-(imidazo[1,2-b] pyridazine-3-yl) acetenyl]-4-methyl-N

BCR-ABL kinase inhibitor and its application (by machine translation)

The present invention relates to the field of chemical medicines, in particular to compounds as represented by formula I having BCR-ABL kinase inhibitory activity, or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and pharmaceutical composition containing the compounds, and application of the compounds or compositions in drug preparation. The compounds of the present invention have strong inhibitory effect on BCR-ABL kinase, and can be used to treat diseases such as tumors.

ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF

The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to compounds having an alkynyl heteroaromatic ring structure and pharmaceutically acceptable salts, stereoisomers, N-oxides, solvates, or prodrugs thereof, an

ALKYNYL HETEROAROMATIC RING COMPOUND AND APPLICATION THEREOF

The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to compounds having an alkynyl heteroaromatic ring structure and pharmaceutically acceptable salts, stereoisomers, N-oxides, solvates, or prodrugs thereof, an

HETEROARYL ALKYNE COMPOUND AND APPLICATION THEREOF

The present invention belongs to the field of pharmaceutical chemistry. Specifically, the invention relates to compounds of general formula I having heteroaryl alkynyl moiety or pharmceutically acceptable salts, isomers, solvates, crystals or prodrugs the